Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS).

Trial Profile

Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS).

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2015

At a glance

  • Drugs Escherichia-coli-strains (Primary)
  • Indications Prostatitis
  • Focus Registrational; Therapeutic Use
  • Sponsors OM Pharma
  • Most Recent Events

    • 13 Sep 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 13 Sep 2013 Primary endpoint 'Clinical-response-rate' has not been met according to results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 12 May 2012 Actual initiation date changed from 6 Nov 2009 to18 Mar 2008 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top